Abstract
BackgroundJanus-activated kinase-1 (JAK1) plays a crucial role in many aspects of cell proliferation, differentiation, apoptosis and immune regulation. However, correlations of JAK1 with prognosis and immune infiltration in NSCLC have not been documented.MethodsWe analyzed the relationship between JAK1 expression and NSCLC prognosis and immune infiltration using multiple public databases.ResultsJAK1 expression was significantly decreased in NSCLC compared with that in paired normal tissues. JAK1 overexpression indicated a favourable prognosis in NSCLC. In subgroup analysis, high JAK1 expression was associated with a preferable prognosis in lung adenocarcinoma (OS: HR, 0.74, 95% CI from 0.58 to 0.95, log-rank P = 0.017), not squamous cell carcinoma. In addition, data from Kaplan–Meier plotter revealed that JAK1 overexpression was associated with a preferable prognosis in male and stage N2 patients and patients without distant metastasis. Notably, increased levels of JAK1 expression were associated with an undesirable prognosis in patients with stage 1 (OS: HR, 1.46, 95% CI from 1.06 to 2.00, P = 0.02) and without lymph node metastasis (PFS: HR, 2.18, 95% CI from 1.06 to 4.46, P = 0.029), which suggests that early-stage NSCLC patients with JAK1 overexpression may have a bleak prognosis. Moreover, multiple immune infiltration cells, including NK cells, CD8 + T and CD4 + T cells, B cells, macrophages, neutrophils, and dendritic cells (DCs), in NSCLC were positively correlated with JAK1 expression. Furthermore, diverse immune markers are associated with JAK1 expression.ConclusionsJAK1 overexpression exhibited superior prognosis and immune infiltration in NSCLC.
Highlights
Lung cancer, as a malignant tumour with high morbidity and mortality, poses a serious threat to people’s physical and mental health [1]
We explored the correlation between Janus-activated kinase-1 (JAK1) expression in Non-small-cell lung cancer (NSCLC) and the abundance of multiple immune cells, including activated CD4 T cells (Act_CD4), activated dendritic cells (Act_DCs), immature dendritic cells, neutrophils, natural killer cells (NKs), plasmacytoid dendritic cells, central memory CD4 cells (Tcm_CD4), and effector memory CD8 cells (Tem_CD8)
JAK1 expression in multiple human tumours We evaluated the differences in JAK1 expression in various human tumour tissues and paired normal tissues using RNA sequencing data from the TCGA
Summary
As a malignant tumour with high morbidity and mortality, poses a serious threat to people’s physical and mental health [1]. Clinical studies have shown that immunotherapy (PD-1/L1 monoclonal antibody, CTLA4 inhibitor) has great potential in the treatment of lung cancer patients without epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations [4]. Immunotherapy only activates immune cells in a subset of patients. With the continuous exploration of the tumour immune microenvironment (TME), which can directly or indirectly affect the development of tumours, including promoting tumour angiogenesis, changing the biological characteristics of the tumour, promoting immune escape, and even regulating the activity of cancer stem cells (CSCs) [5, 6]. Janus-activated kinase-1 (JAK1) plays a crucial role in many aspects of cell proliferation, differentiation, apoptosis and immune regulation. Correlations of JAK1 with prognosis and immune infiltration in NSCLC have not been documented
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
